TEST:

DetermaCNI™

"Oncocyte Corp...announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025."

"Oncocyte Corp...today announced the publication of favorable data regarding its DetermaCNI™ assay...For context, copy number instability (CNI) is a scientifically well-known hallmark of cancer. DetermaCNI™ is a patented approach to measuring CNI for the diagnosis and monitoring of cancer."

Investor Presentation: Submission for reimbursement in 2H24

Investor Presentation

Investor Presentation

"Oncocyte Corporation...announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research. Four abstracts explore the tumor microenvironment and its potential implications for therapeutic response, leveraging expertise and technology behind DetermaIO. A fifth poster highlights exciting study results applying DetermaCNI, Oncocyte’s proprietary therapeutic monitoring blood test, to metastatic pancreatic cancer."

Investor Presentation

"Oncocyte Corporation...announced the publication of data showcasing the clinical utility of its DetermaCNI™ blood-based monitoring test in the peer-reviewed journal Cancers...Results in this peer-reviewed publication demonstrated that DetermaCNI has the potential to address a significant unmet need for patients with primary epithelial ovarian cancer, which is the leading cause of death in gynecological cancers in Western countries."

Investor Presentation